Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence.
Daniel B ChastainTia M StittPhong T LyAndrés F Henao-MartínezCarlos Franco-ParedesSharmon P OsaePublished in: Open forum infectious diseases (2020)
Severe acute respiratory syndrome coronavirus 2 is associated with higher concentrations of proinflammatory cytokines that lead to lung damage, respiratory failure, and resultant increased mortality. Immunomodulatory therapy has the potential to inhibit cytokines and quell the immune dysregulation. Controversial data found improved oxygenation after treatment with tocilizumab, an interleukin-6 inhibitor, sparking a wave of interest and resultant clinical trials evaluating immunomodulatory therapies. The purpose of this article is to assess potential proinflammatory targets and review the safety and efficacy of immunomodulatory therapies in managing patients with acute respiratory distress syndrome associated with coronavirus disease 2019.
Keyphrases
- coronavirus disease
- respiratory syndrome coronavirus
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- respiratory failure
- mechanical ventilation
- clinical trial
- sars cov
- rheumatoid arthritis
- oxidative stress
- human health
- machine learning
- big data
- intensive care unit
- electronic health record
- climate change
- phase ii
- risk factors
- blood flow
- artificial intelligence
- coronary artery disease
- mesenchymal stem cells
- data analysis